Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Penn Pharma Invests £3million in Additional Manufacturing Capacity

Published: Thursday, July 18, 2013
Last Updated: Thursday, July 18, 2013
Bookmark and Share
Penn Pharma has announced its latest plans to invest in additional specific tablet manufacturing and coating capacity to meet customer demand.

This investment is in addition to the £14 million recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.

Penn Pharma Chief Executive Officer, Richard Yarwood, commented: “We are making this additional significant investment to meet our growing customer demands. It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs.  At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers”.

The new £3million investment follows the recent completion of Penn Pharma’s new 15,000 sq ft site for the clinical and commercial manufacture of tablets and capsules. The new industry-leading facility will deliver both the clinical and commercial contained manufacturing needs of its clients.

Penn Pharma Chief Operating Officer, Mark Dean-Netscher, also commented: “Again, we at Penn are demonstrating our commitment to our customers and our growth as a business.  This additional investment will ensure we deliver to our customers and exceed expectations”.

Penn Pharma has been providing pharmaceutical services for over 30 years and employs 275 staff on its two sites in South Wales.  It has twice won the prestigious Queen’s Award for Enterprise in recognition of the work it provides to Export markets including the USA and Japan.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Batch of Coated Tablets at New Penn Facility
International pharmaceutical manufacturer Penn Pharma has successfully completed the first batch of coated tablets in its new contained manufacturing operation.
Wednesday, May 08, 2013
Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!